Full-Time

AI Scientist

Confirmed live in the last 24 hours

Xaira Therapeutics

Xaira Therapeutics

51-200 employees

Biotechnology company focused on drug discovery

No salary listed

Senior, Expert

Daly City, CA, USA

Category
Bioinformatics
Computational Biology
Biology & Biotech
Required Skills
Pytorch
Machine Learning
Requirements
  • PhD in Computer Science, Machine Learning, Computational Chemistry, or a related field.
  • Strong publication record in top-tier conferences or journals (e.g., NeurIPS, ICLR, ICML, Nature, Science, Cell).
  • 5+ years of research experience, including postdoctoral or industry settings, with a track record of leading high-impact AI projects.
  • Deep expertise in modern deep learning frameworks (e.g., PyTorch, JAX) and large-scale model training on GPUs or distributed systems.
  • Demonstrated experience at the intersection of AI and molecular sciences (e.g., cheminformatics, molecular docking, protein modeling).
  • Proven ability to mentor junior researchers and work collaboratively in interdisciplinary environments.
  • Strong communication skills, with experience presenting complex technical work to diverse audiences.
Responsibilities
  • Lead research and development of state-of-the-art deep learning models for molecular modeling, generative chemistry, or related applications.
  • Partner with cross-functional teams in biology, chemistry, and clinical sciences to identify key problems and design innovative AI-driven solutions.
  • Mentor and support a growing team of AI scientists and engineers through technical guidance and collaborative leadership.
  • Publish high-impact research and represent Xaira’s scientific leadership in the broader AI/biotech community.
  • Contribute to technical strategy and the long-term vision for AI within Xaira.
Desired Qualifications
  • Being an active contributor to the open-source or research community is a plus.

Xaira Therapeutics focuses on improving drug discovery and development through the use of artificial intelligence. The company employs machine learning techniques to analyze biological data, which helps in understanding the underlying mechanisms of diseases. By generating extensive datasets, Xaira can create more accurate models that inform the development of new therapies. What sets Xaira apart from its competitors is its integrated approach that combines advanced AI research, data generation, and therapeutic development all under one roof. The goal of Xaira Therapeutics is to transform the way diseases are treated by making the drug development process more efficient and effective.

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$1B

Headquarters

Brisbane, California

Founded

2023

Simplify Jobs

Simplify's Take

What believers are saying

  • Xaira raised over $1 billion in funding, ensuring strong financial backing.
  • Expansion into San Francisco enhances access to biotech talent and collaboration.
  • AI-driven platforms optimize clinical trial designs, reducing time and cost.

What critics are saying

  • Competition from Isomorphic Lab with $600 million funding could challenge Xaira.
  • Rapid expansion into large San Francisco space may strain resources.
  • Multiple new executive appointments could lead to strategic misalignments.

What makes Xaira Therapeutics unique

  • Xaira integrates AI with molecular design for innovative drug discovery.
  • The company leverages insights from functional genomics and proteomics for new medicines.
  • Xaira collaborates with top researchers from the Institute for Protein Design.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Stock Options

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

3%

2 year growth

-1%
Xenoss
May 30th, 2025
Buils an innovative AI platform for drug discovery

Isomorphic Lab secured a record-breaking $600 million Series A in March 2025, and Xaira Therapeutics raised $200 million in 2024.

Aitech365
Apr 4th, 2025
Xaira Therapeutics Appoints Bo Wang as SVP, Head of AI

Xaira Therapeutics announced the appointment of Dr. Bo Wang as SVP and Head of Biomedical AI.

Intelligence360
Jan 6th, 2025
Xaira Therapeutics To Expand Into 73,075 Square Feet Of Space In San Francisco California.

Xaira Therapeutics to expand into 73,075 square feet of space in San Francisco California. Xaira Therapeutics to expand into 73,075 square feet of space in San Francisco California.San Francisco, California — According to state and local development sources, Xaira Therapeutics plans to build out 73,075 square feet of new space in San Francisco. The company plans to occupy the new space in San Francisco, on or about July 1, 2025. According to the company website Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research to better understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area.To learn more about Xaira Therapeutics, visit http://xaira.com/Company Contact:Uplaksh Kumar, Chief Operating [email protected]: http://www.intelligence360.ioCopyright (c) 2024 SI360 Inc

Business Wire
Dec 11th, 2024
Xaira Therapeutics Announces the Appointment of Dr. Paulo Fontoura as Chief Medical Officer and Dr. Hetu Kamisetty as Chief Technology Officer

Xaira Therapeutics announces the appointment of Dr. Paulo Fontoura as Chief Medical Officer and Dr. Hetu Kamisetty as chief technology officer.

TechCrunch
Oct 26th, 2024
VC megadeals are booming - and AI is surprisingly not the top category

Xaira launched in April with a massive $1 billion round led by ARCH Venture Partners and Foresite Labs (both known for biotech), but with classic Silicon Valley VCs in the round, too, like NEA, Sequoia Capital, Lightspeed Venture Partners, SV Angel, and others.